Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Community papers to be digitalised to preserve Aotearoa's historyInternational Women’s Day: How can we have equity when we don't have pockets?Man charged with murder of Ōpōtiki Mongrel Mob Barbarians president Steven TaiatiniPort Waikato candidates fear few even know there is a byTVNZ staff want to know why profitable shows are being cutNational candidate heads to easy victory in Port Waikato byFirearms Minister accused of misleading public on gun statsAll Newshub operations to be shut down, 250 jobs to goSinkhole opens up on busy Auckland road as water main bursts'Highly respected' tramper still missing in Pureora Forest after two weeks
3.1055s , 6502.3671875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Worldly Workshop news portal